Literature DB >> 25140560

Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer's dementia.

Timo S Spehl1, Lars Frings, Sabine Hellwig, Cornelius Weiller, Michael Hüll, Philipp T Meyer, Florian Amtage.   

Abstract

INTRODUCTION: I-FP-CIT SPECT is increasingly used to differentiate between Alzheimer's dementia (AD) and dementia with Lewy bodies (DLB). The role of I-FP-CIT SPECT in frontotemporal dementia (FTD) is rather unclear, albeit nigrostriatal involvement may occur. The aim of this study was to evaluate its role in the differentiation of FTD, DLB, and AD.
METHODS: We analyzed 34 patients with clinical diagnosis of FTD (n = 13), DLB (n = 12), and AD (n = 9) undergoing combined F-FDG PET and I-FP-CIT SPECT. We performed a semiquantitative region of interest-based analysis to determine the binding potential values in caudate nucleus, putamen, and whole striatum including the caudate/putamen binding potential ratio and asymmetry indices. The receiver operating characteristic analyses and multinomial logistic regression were conducted to assess discrimination accuracy.
RESULTS: The putaminal binding potential separated DLB from AD with high accuracy (area under the receiver operating characteristic curve [AUC], 0.94). It also discriminated FTD from DLB with high accuracy (AUC, 0.92), whereas differentiation between FTD and AD was less accurate (AUC, 0.74). The binding potential ratio also provided high accuracy for differentiation of FTD and DLB (AUC, 0.91). Combination of these 2 parameters yielded slightly higher results for differentiation of FTD and DLB (AUC, 0.97). In a group including all patients, accuracy remained very high for DLB (AUC, 0.95), whereas values for FTD (AUC, 0.81) and AD (AUC, 0.80) were lower.
CONCLUSIONS: Semiquantitative assessment of striatal dopamine transporter availability can differentiate between FTD and DLB as well as DLB and AD with high accuracy, whereas discrimination between AD and FTD is limited.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25140560     DOI: 10.1097/RLU.0000000000000554

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

Review 1.  Imaging-based diagnosis of acute renal allograft rejection.

Authors:  Gerold Thölking; Katharina Schuette-Nuetgen; Dominik Kentrup; Helga Pawelski; Stefan Reuter
Journal:  World J Transplant       Date:  2016-03-24

2.  Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts.

Authors:  Melissa J Armstrong; David J Irwin; James B Leverenz; Noheli Gamez; Angela Taylor; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

3.  Differential diagnosis between patients with probable Alzheimer's disease, Parkinson's disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features.

Authors:  Heinrich Garn; Carmina Coronel; Markus Waser; Georg Caravias; Gerhard Ransmayr
Journal:  J Neural Transm (Vienna)       Date:  2017-02-27       Impact factor: 3.575

4.  Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis.

Authors:  Jack L Jennings; Luis R Peraza; Mark Baker; Kai Alter; John-Paul Taylor; Roman Bauer
Journal:  Alzheimers Res Ther       Date:  2022-08-05       Impact factor: 8.823

Review 5.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

6.  Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.

Authors:  Soichiro Shimizu; Kentaro Hirao; Hidekazu Kanetaka; Nayuta Namioka; Hirokuni Hatanaka; Daisuke Hirose; Raita Fukasawa; Takahiko Umahara; Hirohumi Sakurai; Haruo Hanyu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-02       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.